Results 151 to 160 of about 130,661 (316)
Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)
ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang +3 more
wiley +1 more source
Dupilumab and Systemic Hematologic Malignancies: Case Series and Literature Review
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 15%–20% of children and 3%–10% of adults. An increased risk of systemic lymphomas – but not leukemias – has been reported in patients with AD. Dupilumab, a monoclonal IgG4 antibody targeting IL‐4 and IL‐13 signaling, is approved for moderate‐to‐severe AD and is ...
Nello Tommasino +3 more
wiley +1 more source
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson +12 more
wiley +1 more source
PM.79 A Review of Pregnant Women on Tacrolimus and Pregnancy Outcomes in Liverpool [PDF]
S Ballal +3 more
openalex +1 more source
Outcome after steroid withdrawal in adult renal transplant patients receiving tacrolimus-based immunosuppression [PDF]
A Toyofuku +21 more
core +1 more source
Multiglycosidorum tripterygii versus Tacrolimus for rat tracheal allografts [PDF]
Ryoichi Nakanishi, Kosei Yasumoto
openalex +1 more source
Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study
ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis highly associated with systemic comorbidities. Accurate diagnosis and treatment remain challenging due to its rarity and clinical mimickers. Objectives To evaluate demographic, clinical features and treatment outcomes in patients referred with suspected PG at a tertiary ...
David Croitoru +13 more
wiley +1 more source
3D printed tacrolimus suppositories for the treatment of ulcerative colitis
Iria Seoane‐Viaño +6 more
openalex +1 more source

